Novartis Raises Sales Guidance Citing Cancer, Inflammatory Drugs.

Novartis AG has increased its medium-term sales guidance, anticipating growth in revenue due to new cancer, immunological, neurological, and cardiovascular drugs. The company expects a 6% annual revenue growth through 2029, up from its previous guidance of 5%. Novartis is focusing on innovative medicines after streamlining its portfolio by spinning off generics producer Sandoz. The CEO highlighted upcoming developments that will contribute to the company's growth, with shares rising 7.2% this year. [Extracted from the article]